DOCSLIB.ORG

Supplementary Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information Supplementary Information Effects of Renin-Angiotensin System Inhibitors on Mortality and Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis Authors: Surapon Nochaiwong*, Chidchanok Ruengorn, Pajaree Mongkhon, Kednapa Thavorn, Ratanaporn Awiphan, Kajohnsak Noppakun, Surachet Vongsanim, Wilaiwan Chongruksut, Brian Hutton, Manish M. Sood, Greg A. Knoll; for the Thai Renal Outcomes Research (THOR) Investigators *Correspondence and requests for materials: Surapon Nochaiwong, PharmD, Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand, Phone: 66899973365, Fax: 6653222741, Email: [email protected] Supplementary Online Content Appendix 1 Systematic review search strategy S3 Appendix 2 Grey literature from ongoing clinical trial register S14 S2 Appendix 1. Systematic review search strategy: Ovid MEDLINE(R) and Epub Ahead of Print, In- Process & Other Non-Indexed Citations, Daily and Versions(R) 1946 to May 31, 2019 Search Query Items Found #1 exp Peritoneal Dialysis/ 25536 #2 *dialysis, peritoneal/ 13095 #3 exp Continuous Ambulatory Peritoneal Dialysis/ 9861 #4 (Peritoneal Dialysis or Continuous Ambulatory Peritoneal Dialysis).tw,kw,rn. 24380 #5 (PD or CAPD or CCPD or APD or IPD or NIPD or TPD).tw,kw,rn. 139515 #6 or/1-5 158122 #7 exp Renin-Angiotensin System/ 16650 #8 ((Renin-Angiotensin System or RAS) adj (inhibitor* or blockade* or antagonist*)).tw. 2108 #9 Angiotensi*.tw. 103240 #10 or/7-9 107070 #11 6 and 10 1327 #12 exp Angiotensin-converting enzyme inhibitors/ 42532 #13 ((Angiotensin-Converting Enzyme or Angiotensin I-Converting Enzyme or ACE or 32966 Kininase II) adj (inhibitor* or antagonist*)).tw. #14 (ACEI or ACEIs).tw,kw,rn 4064 #15 (Benazepril or Benezepril hydrochloride or Benazepril HCl, or Briem or Cibace or Cibacen 795 or Cibacen CHF or Cibacene or Labopol or Lotensin or Lotrel or Tensanil or Zinadril or 86541-75-5).tw,kw,rn #16 exp Captopril/ 9934 #17 (Captopril or Acediur or Aceplus or Acepress or Acepril or Alopresin or Asisten or 13171 Captoten or Captolane or Captoprilum or Captopryl or Captoril or Cesplon or Dilabar or Farcopril or Garranil or Hypertil or Hypopress or Isopresol or L-Captopril or Lopirin or Lopril or Novocaptopril or Tenosbon or Tensoprel or Zapto or 62571-86-2).tw,kw,rn #18 exp Cilazapril/ 535 #19 (Cilazapril or Dynorm or Inhibace or Vascace or 88768-40-5).tw,kw,rn 637 #20 (Delapril or alindapril or Delaket or Adecut or Beniod or 83435-66-9).tw,kw,rn 155 #21 exp Enalapril/ 6612 #22 (Enalapril or Bonuten or Enalaprila or Enalaprilum or Gadopril or Kinfil or 75847-73- 8456 3).tw,kw,rn #23 exp Fosinopril/ 418 #24 (Fosinopril or Dynacil or Fosenopril or Fosinil or Fosinorm or Fositens or Fozitec or 590 Hiperlex or Monopril or Newace or Staril or Tenso Stop or Tensocardil or 98048-97- 6).tw,kw,rn #25 (Imidapril or Tanatril or 89371-37-9).tw,kw,rn 287 #26 exp Lisinopril/ 2014 #27 (Lisinopril or Lisinopril dehydrate or Prinivil or Renacor or Zestril or 83915-83-7).tw,kw,rn 2883 #28 (Moexipril or Univasc or 103775-10-6).tw,kw,rn 109 #29 exp Perindopril/ 1675 #30 (Perindopril or Aceon or Covapril or Coversyl or Pirindopril or Prestarium or 82834-16- 2164 0).tw,kw,rn #31 exp Quinapril/ 631 #32 (Quinapril or Quinapril hydrochloride or Quinapril HCl or Accupril or Accuprin or 974 Accupron or Acequin or Acuitel or Acuprel or Asig or Conan or Continucor or Ectren or Hemokvin or Korec or Koretic or Lidaltrin or Quinazil or 85441-61-8).tw,kw,rn #33 exp Ramipril/ 1998 S3 #34 (Ramipril or Acovil or Altace or Carasel or Cardace or Delix or Hytren or Lostapres or 5346 Naprix or Pramace or Quark or Ramace or Ramiprilum or Ramipro or Triatec or Tritace or Vesdil or Zabien or 87333-19-5).tw,kw,rn #35 (Spirapril or Renormax or 83647-97-6).tw,kw,rn 144 #36 (Temocapril or Temocaprilum or Acecol or 111902-57-9).tw,kw,rn 184 #37 (Trandolapril or Gopten or Mavik or Odrik or Udrik or 87679-37-6).tw,kw,rn 704 #38 (Zofenopril or Zocardis or 81872-10-8).tw,kw,rn 187 #39 or/12-38 62507 #40 6 and 39 423 #41 exp Angiotensin Receptor Antagonists/ 22632 #42 exp Angiotensin II Type 1 Receptor Blockers/ 17269 #43 ((angiotensin or AT 2 receptor) adj3 (antagonist* or block*)).tw 19190 #44 (Sartan or Sartans).tw,kw,rn. 292 #45 (ARB or ARBs).tw,kw,rn. 6277 #46 (Azilsartan or Azilsartan medoxomil or Edarbi or 147403-03-0).tw,kw,rn. 192 #47 (Candesartan or Candesartan cilexetil or Amias or Atacand or Blopress or Ratacand or 3172 139481-59-7).tw,kw,rn. #48 (Eprosartan or Teveten or 133040-01-4).tw,kw,rn. 390 #49 (Fimasartan or Fimanta or Fimagen or Kanarb or 247257-48-3).tw,kw,rn. 83 #50 exp Irbesartan/ 1198 #51 (Irbesartan or Aprovel or Avapro or Karvea or 138402-11-6).tw,kw,rn. 1785 #52 exp Losartan/ 6548 #53 (Losartan or Cozaar or Losartan Monopotassium Salt or Lorsartan Potassium or 114798-26- 9501 4).tw,kw,rn. #54 (Olmesartan or Olmesartan medoxomil or Benicar or Omesartan or Olmetec or Votum or 1555 144689-63-4).tw,kw,rn. #55 (Tasosartan or 145733-36-4).tw,kw,rn. 16 #56 exp Telmisartan/ 1598 #57 (Telmisartan or Kinzalmono or Micardis or Pritor or 144701-48-4).tw,kw,rn. 2282 #58 exp Valsartan/ 2185 #59 (Valsaetan or Diovan or Kalpress or Miten or Nisis or Provas or Tareg or Vals or Valtan or 2171 Valzaar or 137862-53-4).tw,kw,rn. #60 or/41-59 37772 #61 6 and 60 936 #62 11 or 40 or 61 1488 #63 exp Adolescent/ not (exp Adult/ and Adolescent/) 578726 #64 exp Child/ not (exp Adult/ and exp Child/) 1160496 #65 exp Infant/ not (exp Adult/ and exp Infant/) 805603 #66 or/63-65 1804229 #67 62 not 66 1461 #68 exp Animals/ not (Humans/ and exp Animals/) 4585086 #69 67 not 68 589 #70 (comment or editorial or interview or letter or news or newspaper article).pt. 1955104 #71 69 not 70 571 #72 randomized controlled trial/ or controlled clinical trial/ 571256 #73 (randomi#ed or randomly or RCT$1 or placebo*).tw,kw. 905371 #74 ((singl* or doubl* or trebl* or tripl*) adj (mask* or blind* or dumm*)).tw,kw. 164134 #75 trial.ti. 199418 #76 controlled clinical trial/ 93091 S4 #77 (control* adj2 trial*).tw,kw. 244591 #78 or/72-77 1164272 #79 71 and 78 61 #80 (nRCT or nRCTs or non-RCT?).tw,kw. 763 #81 (control* adj3 ("before and after" or "before after")).tw,kw. 4009 #82 (time series adj3 interrupt*).tw,kw. 2527 #83 (pre- adj3 post-).tw,kw. 73888 #84 (pretest adj3 posttest).tw,kw. 4986 #85 (control* adj2 stud$3).tw,kw. 216965 #86 control group/ 1620 #87 (control* adj2 group$1).tw,kw. 465988 #88 or/80-87 725660 #89 71 and 88 34 #90 exp comparative study/ 1831067 #91 ((comparative or comparison) adj (study or studies)).tw,kw. 103950 #92 exp cohort study/ 1862035 #93 (cohort* adj2 stud$3).tw,kw. 197141 #94 exp case control study/ 995765 #95 ((case-control* or case-based or case-comparison) adj (study or studies)).tw,kw. 98609 #96 or/90-95 3693772 #97 71 and 96 120 #98 79 or 89 or 97 173 S5 Appendix 1. Systematic review search strategy: OVID Embase Classic + Embase 1947 to 2019 May 31 (continued) Search Query Items Found #1 exp Peritoneal Dialysis/ 41740 #2 *dialysis, peritoneal/ 17899 #3 exp Continuous Ambulatory Peritoneal Dialysis/ 12442 #4 (Peritoneal Dialysis or Continuous Ambulatory Peritoneal Dialysis).tw,kw,rn. 32634 #5 (PD or CAPD or CCPD or APD or IPD or NIPD or TPD).tw,kw,rn. 217976 #6 or/1-5 246059 #7 exp Renin-Angiotensin System/ 38979 #8 ((Renin-Angiotensin System or RAS) adj (inhibitor* or blockade* or antagonist*)).tw. 3078 #9 Angiotensi*.tw. 136714 #10 or/7-9 148208 #11 6 and 10 2983 #12 exp Angiotensin-Converting Enzyme Inhibitors/ 167567 #13 ((Angiotensin-Converting Enzyme or Angiotensin I-Converting Enzyme or ACE or 46687 Kininase II) adj (inhibitor* or antagonist*)).tw. #14 (ACEI or ACEIs).tw,kw,rn 8374 #15 exp Benazepril/ 3485 #16 (Benazepril or Benezepril hydrochloride or Benazepril HCl, or Briem or Cibace or Cibacen 3360 or Cibacen CHF or Cibacene or Labopol or Lotensin or Lotrel or Tensanil or Zinadril or 86541-75-5).tw,kw,rn #17 exp Captopril/ 33873 #18 (Captopril or Acediur or Aceplus or Acepress or Acepril or Alopresin or Asisten or 35071 Captoten or Captolane or Captoprilum or Captopryl or Captoril or Cesplon or Dilabar or Farcopril or Garranil or Hypertil or Hypopress or Isopresol or L-Captopril or Lopirin or Lopril or Novocaptopril or Tenosbon or Tensoprel or Zapto or 62571-86-2).tw,kw,rn #19 exp Cilazapril/ 1938 #20 (Cilazapril or Dynorm or Inhibace or Vascace or 88768-40-5).tw,kw,rn 1972 #21 exp Delapril/ 425 #22 (Delapril or alindapril or Delaket or Adecut or Beniod or 83435-66-9).tw,kw,rn 435 #23 exp Enalapril/ 25551 #24 (Enalapril or Bonuten or Enalaprila or Enalaprilum or Gadopril or Kinfil or 75847-73- 28104 3).tw,kw,rn #25 exp Fosinopril/ 3029 #26 (Fosinopril or Dynacil or Fosenopril or Fosinil or Fosinorm or Fositens or Fozitec or 3091 Hiperlex or Monopril or Newace or Staril or Tenso Stop or Tensocardil or 98048-97- 6).tw,kw,rn #27 exp Imidapril/ 837 #28 (Imidapril or Tanatril or 89371-37-9).tw,kw,rn 848 #29 exp Lisinopril/ 15041 #30 (Lisinopril or Lisinopril dehydrate or Prinivil or Renacor or Zestril or 83915-83-7).tw,kw,rn 15340 #31 exp Moexipril/ 469 #32 (Moexipril or Univasc or 103775-10-6).tw,kw,rn 465 #33 exp Perindopril/ 8215 #34 (Perindopril or Aceon or Covapril or Coversyl or Pirindopril or Prestarium or 82834-16- 8600 0).tw,kw,rn #35 exp Quinapril/ 3418 S6 #36 (Quinapril or Quinapril hydrochloride or Quinapril HCl or Accupril or Accuprin or 3791 Accupron or Acequin or Acuitel or Acuprel or Asig or Conan or Continucor or Ectren or Hemokvin or Korec or Koretic or Lidaltrin or Quinazil or 85441-61-8).tw,kw,rn
Load more

Recommended publications
  • Effects of Monotherapy of Temocapril Or Candesartan with Dose Increments Or Combination Therapy with Both Drugs on the Suppression of Diabetic Nephropathy
    325 Hypertens Res Vol.30 (2007) No.4 p.325-334 Original Article Effects of Monotherapy of Temocapril or Candesartan with Dose Increments or Combination Therapy with Both Drugs on the Suppression of Diabetic Nephropathy Susumu OGAWA1), Kazuhisa TAKEUCHI1), Takefumi MORI1), Kazuhiro NAKO1), Yoshitaka TSUBONO2),3), and Sadayoshi ITO1) We examined the effects of increasing the recommended initial doses of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), or of switching to combination therapy with both drugs, on diabetic nephropathy. Hypertensive type 2 diabetic patients with urinary albumin excretion (ACR) between 100 and 300 mg/g creatinine (Cre) were assigned to the following five groups in which an antihy- pertensive drug was administered at a recommended initial dose for 48 weeks, and then either the dose was doubled or an additional drugs was added to regimen for the following 48 weeks: N, nifedipine-CR (N) 20 mg/day (initial dose); T, ACEI temocapril (T) 2 mg/day; C, ARB candesartan (C) 4 mg/day; T+C, T first and then addition of C; C+T, C first and then addition of C. ACR decreased in the T (n=34), C (n=40), T+C (n=37) and C+T (n=35) groups, but not in the N group (n=18). However, the anti-proteinuric effect was less in the T than in the C, T+C or C+T groups, while no differences existed among the latter three. In each group, there were significant linear relationships between attained BP and ACR; however, the regression lines were shifted toward lower ACR level in the renin-angiotensin system–inhibition groups compared with the N group.
    [Show full text]
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy
    929 Hypertens Res Vol.30 (2007) No.10 p.929-935 Original Article Renoprotective Effect of the Addition of Losartan to Ongoing Treatment with an Angiotensin Converting Enzyme Inhibitor in Type-2 Diabetic Patients with Nephropathy Hirohiko ABE1), Shinya MINATOGUCHI1), Hiroshige OHASHI1), Ichijiro MURATA1), Taro MINAGAWA1), Toshio OKUMA1), Hitomi YOKOYAMA1), Hisato TAKATSU1), Tadatake TAKAYA1), Toshihiko NAGANO1), Yukio OSUMI1), Masao KAKAMI1), Tatsuo TSUKAMOTO1), Tsutomu TANAKA1), Kunihiko HIEI1), and Hisayoshi FUJIWARA1) Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are fre- quently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albumin- uria- or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n=14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n=20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was inef- fective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. Dur- ing the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively.
    [Show full text]
  • Role of the Central Renin‑Angiotensin System in Hypertension (Review)
    INTERNATIONAL JOURNAL OF MOleCular meDICine 47: 95, 2021 Role of the central renin‑angiotensin system in hypertension (Review) CHUANXIN SU1,2*, JINHUA XUE2,3*, CHAO YE1 and AIDONG CHEN1,2 1Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center of Translational Medicine for Cardiovascular Disease, Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China; 2Research Center for Cardiovascular and Cerebrovascular Diseases, The University of Duisburg‑Essen, Duisburg‑Essen University, d‑45122 Essen, Germany; 3Department of Physiology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China Received May 8, 2020; Accepted January 25, 2021 DOI: 10.3892/ijmm.2021.4928 Abstract. Present in more than one billion adults, hyper‑ the effect of ATR1. Their mechanisms of action are related to tension is the most significant modifiable risk factor for pro‑inflammatory and sympathetic excitatory effects. Central mortality resulting from cardiovascular disease. Although its AT1R is involved in almost all types of hypertension, including pathogenesis is not yet fully understood, the disruption of the spontaneous hypertension, salt‑sensitive hypertension, renin‑angiotensin system (RAS), consisting of the systemic obesity‑induced hypertension, renovascular hypertension, and brain RAS, has been recognized as one of the primary diabetic hypertension, L‑NAME‑induced hypertension, reasons for several types of hypertension. Therefore, acquiring stress‑induced hypertension, angiotensin II‑induced hyper‑ sound knowledge of the basic science of RAS and the under‑ tension and aldosterone‑induced hypertension. There are lying mechanisms of the signaling pathways associated 2 types of central AT1R blockade, acute blockade and chronic with RAS may facilitate the discovery of novel therapeutic blockade.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Fimasartan Clinical Trial: Direction for Acute Myocardial Infarction
    Myung Ho Jeong, MD, PhD, FACC, FAHA, FESC, FSCAI, FAPSIC Professor, Principal Investigator of Korea Acute Myocardial Infarction Registry, Director of Heart Research Center Designated by Korea Ministry of Health and Welfare, Director of Korea Cardiovascular Stent Research Institute, Chonnam National University Hospital, Gwangju, Korea Losartan Valsartan Irbesartan N M3C N M3C CH3 HN HN N N HN N HO N N N N N N N CH O 3 O N O HO O N CH3 Candesartan Olmesartan Telmisartan O N O HN N O HO N O CH3 HO O N O O HN N N CH3 N N N N HO CH O M C N 3 N 3 N CH3 CH3 CH3 CH3 Ries et al. J Med Chem 1993;36:4040–4051 2 c a b Brand Name: KANARB (KHAN of ARBs) Active Pharmaceutical Ingredient: Fimasartan potassium trihydrate, C27H30N7OS·K·3H2O Molecular Weight = 593.79 pH = 6~8 (water, 50mg/10mL) T1/2(hr) : 7-10 Solubility: freely soluble in MeOH, soluble in EtOH, slightly soluble in water 3 AT1 receptor Fimasartan By Discovery Studio 2.5, Accelys Inc., CA, USA 4 Losartan Valsartan Irbesartan Eprosartan Telmisartan Olmesartan Candesartan Fimasartan Tmax (hr) 3-4 2-4 1.5-2 1-2 0.5-1 1-2 3-4 0.5~3 2 T1/2 (hr) (EXP3174: 6-9 11-15 5-9 24 13 5-9 7-10 6-9) Active EXP3174 None None None None None None None metabolite Protein 99 95 90-92 98 99.5 99 >99 >97 Binding (%) Bioavailability 33 10-35 60-80 13 42-58 26 15 30-40 (%) Urinary 35 13 20 7 <1 35-50 33-59 <3 Elimination (%) Dose*1 (mg) 25, 50, 100 40,80,60,320 75, 150,300 400, 600 20, 40, 80 5, (10*2), 20, 40 4, 8, 16, 32 60, 120 AT1 binding Competitive Competitive Competitive Competitive Non-competitive Non-competitive
    [Show full text]
  • Combination Therapy with Olmesartan and Temocapril Ameliorates Renal Damage and Upregulates the Klotho Gene in 5/6 Nephrectomized Spontaneously Hypertensive Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Tottori University Research Result Repository Yonago Acta medica 2009;52:27–35 Combination Therapy with Olmesartan and Temocapril Ameliorates Renal Damage and Upregulates the klotho Gene in 5/6 Nephrectomized Spontaneously Hypertensive Rats Satoko Maeta, Chishio Munemura, Takeaki Fukui, Chihiro Ishida and Yoshikazu Murawaki Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504 Japan Recent studies suggest that chronic kidney disease may induce cardiovascular disease through oxidative stress, and that the aging suppressor gene klotho reduces oxidative stress in the kidney. In this study, we examined the changes in klotho gene expression, and the renoprotective effects of olmesartan (OLM), angiotensin II receptor blocker (ARB) alone or in combination with temocapril (TEM), angiotensin-converting enzyme inhibitor (ACEI) in 5/6-nephrectomized (5/6-Nx) spontaneously hypertensive rats. Male 5/6-Nx spontane- ously hypertensive rats were randomly assigned to 5 groups as follows: control group; 5/6-Nx group, 5/6-Nx rats; low OLM group, 5/6-Nx rats administered low-dose OLM (3 mg/kg/day); high OLM group, 5/6-Nx rats administered high-dose OLM (10 mg/kg/day); OLM+TEM group, 5/6-Nx rats administered high-dose OLM and TEM (10 mg/kg/day each). These drugs were administered for 12 weeks. Systolic blood pressure, glomerular sclerosis and transforming growth factor beta 1 mRNA in high OLM and OLM+TEM groups were significantly lower than that in the 5/6-Nx group.
    [Show full text]
  • "Coaprovel, INN-Irbesartan+Hydrochlorothiazide"
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CoAprovel 150 mg/12.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. Excipient with known effect: Each tablet contains 26.65 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1). 4.2 Posology and method of administration Posology CoAprovel can be taken once daily, with or without food. Dose titration with the individual components (i.e. irbesartan and hydrochlorothiazide) may be recommended. When clinically appropriate direct change from monotherapy to the fixed combinations may be considered: . CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; . CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg. CoAprovel 300 mg/25 mg may be administered in patients insufficiently controlled by CoAprovel 300 mg/12.5 mg. Doses higher than 300 mg irbesartan/25 mg hydrochlorothiazide once daily are not recommended. When necessary, CoAprovel may be administered with another antihypertensive medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).
    [Show full text]
  • Hypertension and Cardiac Arrhythmias: a Review of the Epidemiology, Pathophysiology and Clinical Implications
    Journal of Human Hypertension (2008) 22, 380–388 & 2008 Nature Publishing Group All rights reserved 0950-9240/08 $30.00 www.nature.com/jhh REVIEW Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications K-H Yiu and H-F Tse Division of Cardiology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China Hypertension is commonly associated with cardiac cular ectopy and sudden cardiac death. Recent arrhythmias in patients with and without concomitant prospective clinical trials reveal that antihyper- cardiovascular disease. Experimental and epidemiolo- tensive therapy may delay or prevent the occurrence gical studies have demonstrated potential links of cardiac arrhythmias and sudden cardiac death in between hypertension and atrial and ventricular arrhyth- patients with hypertension. Although antihypertensive mias, although the underlying pathophysiological me- agents that block the renin–angiotensin–aldosterone chanism remains unclear. Nonetheless, the importance system appear to protect against cardiac arrhythmias, of hypertension as a cause of atrial and ventricular this needs to be confirmed by current ongoing clinical arrhythmias is not well recognized. In particular, trials. the occurrence of left ventricular hypertrophy is a Journal of Human Hypertension (2008) 22, 380–388; strong predictor for the development of AF, ventri- doi:10.1038/jhh.2008.10; published online 13 March 2008 Keywords: atrial fibrillation; arrhythmia; sudden cardiac death Introduction Epidemiology Concomitant cardiac arrhythmias are commonly Atrial fibrillation seen in patients with hypertension, although the Atrial fibrillation is the most common sustained mechanism of this association is unclear. The arrhythmia in adults and is associated with an contribution of hypertension to the development of increased risk for cardiovascular morbidity, mortality atrial and ventricular arrhythmias is unrecognized and stroke.1,2 The incidence of AF increases with age; and thus undertreated.
    [Show full text]
  • “Captopril” [Mesh
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Open Heart PubMed: 1. (“dose comparison” OR “dose” OR “low dose” OR “high dose” OR “dosage*”) 2. (“captopril” [mesh] OR “Benazepril” OR “Enalapril” [mesh] OR “Enalapril” OR “Cilazapril” [mesh] OR “Cilazapril” OR “Delapril” OR “Imidapril” OR “Lisinopril” [mesh] OR “Lisinopril” OR “Moexipril” OR “Perindopril” [mesh] OR “Perindopril” OR “Quinapril” OR “Ramipril” [mesh] “Ramipril” OR “Spirapril” OR “Temocapril” OR “Trandolapril” OR “Zofenopril” OR “Enalaprilat” [mesh] OR “Enalaprilat” OR “Fosinopril” [mesh] OR “Fosinopril” OR “Teprotide” [mesh] OR “Teprotide” OR “Angiotensin-Converting Enzyme Inhibitors” [mesh] OR “Angiotensin-Converting Enzyme Inhibitors” OR “Angiotensin Converting Enzyme Inhibitors” OR “Inhibitors, Kininase II” OR “Kininase II Antagonists” OR “Kininase II Inhibitors” OR “Angiotensin I-Converting Enzyme Inhibitors” OR “Angiotensin I Converting Enzyme Inhibitors” OR “Antagonists, Angiotensin- Converting Enzyme” OR “Antagonists, Angiotensin Converting Enzyme” OR “Antagonists, Kininase II” OR “Inhibitors, ACE” OR “ACE Inhibitors” OR “Inhibitors, Angiotensin-Converting Enzyme” OR “Enzyme Inhibitors, Angiotensin-Converting” OR “Inhibitors, Angiotensin Converting Enzyme” OR “Angiotensin-Converting Enzyme Antagonists” OR “Angiotensin Converting Enzyme Antagonists” OR “Enzyme Antagonists, Angiotensin-Converting”) 3. (“Heart failure” [mesh] OR “heart failure” OR “Cardiac Failure” OR “Heart Decompensation” OR “Decompensation, Heart” OR “Heart Failure, Right-Sided” OR “Heart Failure, Right Sided” OR “Right-Sided Heart Failure” OR “Right Sided Heart Failure” OR “Myocardial Failure” OR “Congestive Heart Failure” OR “Heart Failure, Congestive” OR “Heart Failure, Left-Sided” OR “Heart Failure, Left Sided” OR “Left-Sided Heart Failure” OR “Left Sided Heart Failure” OR “chronic heart failure” OR "chronic heart" OR (CHF)) 4.
    [Show full text]
  • Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
    ORIGINAL ARTICLE Cardiovascular Disorders http://dx.doi.org/10.3346/jkms.2015.30.1.34 • J Korean Med Sci 2015; 30: 34-43 Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction Doo Sun Sim,1 Myung Ho Jeong,1 Cardioprotective effect of fimasartan, a new angiotensin receptor blocker (ARB), was Ho Chun Song,2 Jahae Kim,2 Ari Chong,2 evaluated in a porcine model of acute myocardial infarction (MI). Fifty swine were Hee Seung Bom,2 In Seok Jeong,3 randomized to group 1 (sham, n = 10), group 2 (no angiotensin-converting enzyme Sang Gi Oh,3 Jong Min Kim,1 inhibitor [ACEI] or ARB, n = 10), group 3 (perindopril 2 mg daily, n = 10), group 4 1 1 Dae Sung Park, Jung Ha Kim, (valsartan 40 mg daily, n = 10), or group 5 (fimasartan 30 mg daily, n = 10). Acute MI was 1 1 Kyung Seob Lim, Min Suk Kim, induced by occlusion of the left anterior descending artery for 50 min. Echocardiography, 1 1 Shi Hyun Ryu, Hyun Kuk Kim, single photon emission computed tomography (SPECT), and F-18 fluorodeoxyglucose Sung Soo Kim,1 Su Young Jang,1 1 1 cardiac positron emission tomography (PET) were performed at baseline, 1 week, and 4 Jae Yeong Cho, Hae Chang Jeong, weeks. Iodine-123 meta-iodobenzylguanidine (MIBG) scan was done at 6 weeks for Ki Hong Lee,1 Keun Ho Park,1 visualization of cardiac sympathetic activity. Left ventricular function and volumes at 4 Nam Sik Yoon,1 Hyun Ju Yoon,1 weeks were similar between the 5 groups.
    [Show full text]
  • Quantify Chronic Kidney Disease Clinical Outcomes Database
    Quantify Chronic Kidney Disease Clinical Outcomes Database Summary Information The current version of the database includes clinical safety and efficacy information on treatment options currently approved or in development for Chronic Kidney Disease (CKD) progression Features and Benefits in patients with Type 2 Diabetes Mellitus (T2DM) and overt Key Features albuminuria/proteinuria, as well as patients with IGA nephropathy. • Comprehensive: includes information for marketed drugs; data sources include journal publications, conference posters, Table 1. Summary information regulatory reviews, etc Parameter Description • Ease of tracking: all clinical trial publications are listed in a format Excel or KEEP format indications iga nephropathy, diabetic nephropathy, separate source database and linked to unique clinical trial names nephropathy, proteinuria • Flexibility: the database design allows for quick updates as references 99 well as expansions to include additional indications/drugs/ trials 88 endpoints/trials trial.arms 214 patients 17,364 • Model-friendliness: designed and reviewed by experienced data.rows 5,456 modelers to ensure highest quality and usability for modeling compounds aliskiren, amlodipine, atenolol, atrasentan, and simulation to support drug development strategies avosentan, azathioprine, azelnidipine, bardoxolone methyl, benazepril, canagliflozin, • Customizability: can be augmented with clinical trial data candesartan cilexetil, captopril, chlorthalidone, proprietary to the client (this information goes into a separate
    [Show full text]